Drug Profile
Research programme: macrocyclic therapeutics - Boehringer Ingelheim/Spexis
Latest Information Update: 16 Feb 2022
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; Polyphor
- Developer Boehringer Ingelheim; Spexis
- Class Macrocyclic compounds
- Mechanism of Action Protein modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Undefined in Switzerland (PO)
- 31 Jul 2013 Early research is ongoing in Switzerland
- 12 Jun 2012 Early research in Undefined indication in Switzerland (PO)